In the BioHarmony Drug Report Database
Isatuximab
Sarclisa (isatuximab) is an antibody pharmaceutical. Isatuximab was first approved as Sarclisa on 2020-03-02. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Trade Name
|
Sarclisa |
|---|---|
Common Name
|
isatuximab |
ChEMBL ID
|
CHEMBL3545131 |
Indication
|
multiple myeloma |
Drug Class
|
Monoclonal antibodies: chimeric, tumors as target |
Image (chem structure or protein)
